Finance

Lists
Why is AVLN up 3.65%?
Dive Deeper
AVLN:NASDAQ
Avalyn Pharma Inc
$28.70
+3.65%
(+1.01) 1D
$28.14
-1.95% (-0.56)
After hours
Closed: Nov 19, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVLN...
Open
$27.86
High
$28.90
Low
$27.01
Mkt. cap
1.28B
Avg. vol.
449.98K
Volume
0.00
52-wk high
$40.17
52-wk low
$22.24
EPS
-$2.86
No. of employees
56
Open
$27.86
High
$28.90
Low
$27.01
Mkt. cap
1.28B
Avg. vol.
449.98K
Volume
0.00
52-wk high
$40.17
52-wk low
$22.24
EPS
-$2.86
No. of employees
56
News stories
From web sources and news partners
About Avalyn Pharma Inc
CEO-
Employees56
Founded2011
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 2 analysts giving stock ratings to AVLN in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for AVLN in the last 3 months.
Highest
Current $28.70
$60.00 (+109.06%)
Average
$56.50 (+96.86%)
Lowest
$53.00 (+84.67%)
Analyst
Recommendation
Action
Price target
Projected
Date
Maxwell Skor
Morgan Stanley
Buy
Reiterated
$53.00
+84.7%
11/16/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
$53.00
+84.7%
11/16/2026
Tiago Fauth
Raymond James
Buy
Initiated
$60.00
+109.1%
10/02/2026
Roger Song
Jefferies
Buy
Maintained
$52.00
+81.2%
08/13/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Initiated
$51.00
+77.7%
05/26/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$0.67 / -$0.75
+10.67%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
22.09M
22.89M
24.73M
25.49M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.23M
5.02M
6.56M
7.60M
Operating expense
25.32M
27.91M
31.29M
33.09M
Total operating expenses
25.32M
27.91M
31.29M
33.09M
Operating income
-25.32M
-27.91M
-31.29M
-33.09M
Other non operating income
-53.00K
13.00K
-69.00K
-40.00K
EBT including unusual items
-23.58M
-26.87M
-28.94M
-29.66M
EBT excluding unusual items
-23.58M
-26.87M
-28.94M
-29.66M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-23.58M
-26.87M
-28.94M
-29.66M
Net profit margin
-
-
-
-
Earnings per share
-
-21.83
-0.98
-0.67
Interest and investment income
1.79M
1.12M
2.70M
3.76M
Interest expense
-1.00K
-98.00K
-272.00K
-277.00K
Net interest expenses
1.79M
1.03M
2.42M
3.48M
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.31M
-27.85M
-31.18M
-32.99M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps